A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and platinum-based chemotherapy - LOTOS

Study identifier:AZ-RU-00001

ClinicalTrials.gov identifier:NCT05941897

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase II, Open-label, Multicentre, Non-comparative, Single-arm Local Study of Ceralasertib Plus Durvalumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

Medical condition

Advanced or Metastatic NSCLC

Phase

Phase 2

Healthy volunteers

No

Study drug

Ceralasertib, Durvalumab

Sex

All

Actual Enrollment

39

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 21 Jun 2023
Primary Completion Date: 29 Jul 2024
Estimated Study Completion Date: 29 Jul 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria